FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308182012> ?p ?o ?g. }

• W4308182012 endingPage "132" @default.
• W4308182012 startingPage "117" @default.
• W4308182012 abstract "Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD.Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews.The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most (n = 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments.The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence.Patients with hemorrhoidal disease (HD) can experience recurring disease following a period of improvement or remission. It is not well established how often this might happen, who is at greatest risk, or which treatments can reduce this risk. In this study, a systematic literature review (SLR) was conducted to summarize evidence on the occurrence and recurrence of HD, as well as treatment effectiveness. Several literature databases were searched for articles that described real-world evidence (RWE) studies reporting the epidemiology or recurrence of HD as well as published SLRs that combined the results of multiple studies (meta-analyses) on treatment for adults with HD. Forty of 2037 articles identified by the search were considered relevant, and four others identified by clinicians were also included (total = 44; 39 RWE, 5 meta-analyses). Review of the RWE articles revealed that HD epidemiology was determined differently between studies. Only 23 reported recurrence rates (up to 56.5%) after surgery or treatment with phlebotonic drugs (drugs that improve blood flow in veins). Most (19/23) reported recurrence rates of 20% or less. Risk factors for recurrence were similar to usual HD risk factors (e.g., constipation, male gender, age) in addition to time since treatment. Phlebotonic agents, including those made from plant extracts (micronized purified flavonoid fractions, MPFFs) improved hemorrhoidal symptoms compared with placebo or no treatment. In one meta-analysis, MPFF was the only phlebotonic to significantly reduce recurrence risk versus no treatment or placebo. Overall, more research is needed to compare treatments and determine optimal treatment duration to prevent recurrence. Author-narrated video abstract." @default.
• W4308182012 created "2022-11-09" @default.
• W4308182012 creator A5005842069 @default.
• W4308182012 creator A5016548976 @default.
• W4308182012 creator A5021903078 @default.
• W4308182012 creator A5029656810 @default.
• W4308182012 creator A5030689194 @default.
• W4308182012 creator A5047914101 @default.
• W4308182012 creator A5054982943 @default.
• W4308182012 creator A5068489539 @default.
• W4308182012 creator A5072418661 @default.
• W4308182012 creator A5081637136 @default.
• W4308182012 date "2022-11-04" @default.
• W4308182012 modified "2023-10-04" @default.
• W4308182012 title "Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review" @default.
• W4308182012 cites W1734706510 @default.
• W4308182012 cites W1969615019 @default.
• W4308182012 cites W2004509488 @default.
• W4308182012 cites W2049343040 @default.
• W4308182012 cites W2064509332 @default.
• W4308182012 cites W2114488753 @default.
• W4308182012 cites W2130686415 @default.
• W4308182012 cites W2176156840 @default.
• W4308182012 cites W2211214498 @default.
• W4308182012 cites W2332235750 @default.
• W4308182012 cites W2592063621 @default.
• W4308182012 cites W2592238153 @default.
• W4308182012 cites W2756578555 @default.
• W4308182012 cites W2796980824 @default.
• W4308182012 cites W2803442577 @default.
• W4308182012 cites W2887268224 @default.
• W4308182012 cites W2911808238 @default.
• W4308182012 cites W2972963231 @default.
• W4308182012 cites W3025417223 @default.
• W4308182012 cites W3118615836 @default.
• W4308182012 cites W3157727189 @default.
• W4308182012 doi "https://doi.org/10.1007/s12325-022-02351-7" @default.
• W4308182012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36331754" @default.
• W4308182012 hasPublicationYear "2022" @default.
• W4308182012 type Work @default.
• W4308182012 citedByCount "0" @default.
• W4308182012 crossrefType "journal-article" @default.
• W4308182012 hasAuthorship W4308182012A5005842069 @default.
• W4308182012 hasAuthorship W4308182012A5016548976 @default.
• W4308182012 hasAuthorship W4308182012A5021903078 @default.
• W4308182012 hasAuthorship W4308182012A5029656810 @default.
• W4308182012 hasAuthorship W4308182012A5030689194 @default.
• W4308182012 hasAuthorship W4308182012A5047914101 @default.
• W4308182012 hasAuthorship W4308182012A5054982943 @default.
• W4308182012 hasAuthorship W4308182012A5068489539 @default.
• W4308182012 hasAuthorship W4308182012A5072418661 @default.
• W4308182012 hasAuthorship W4308182012A5081637136 @default.
• W4308182012 hasBestOaLocation W43081820121 @default.
• W4308182012 hasConcept C107130276 @default.
• W4308182012 hasConcept C118552586 @default.
• W4308182012 hasConcept C120665830 @default.
• W4308182012 hasConcept C121332964 @default.
• W4308182012 hasConcept C126322002 @default.
• W4308182012 hasConcept C141071460 @default.
• W4308182012 hasConcept C17744445 @default.
• W4308182012 hasConcept C1862650 @default.
• W4308182012 hasConcept C189708586 @default.
• W4308182012 hasConcept C198451711 @default.
• W4308182012 hasConcept C199539241 @default.
• W4308182012 hasConcept C27415008 @default.
• W4308182012 hasConcept C2779134260 @default.
• W4308182012 hasConcept C2779473830 @default.
• W4308182012 hasConcept C61511704 @default.
• W4308182012 hasConcept C71924100 @default.
• W4308182012 hasConcept C95190672 @default.
• W4308182012 hasConceptScore W4308182012C107130276 @default.
• W4308182012 hasConceptScore W4308182012C118552586 @default.
• W4308182012 hasConceptScore W4308182012C120665830 @default.
• W4308182012 hasConceptScore W4308182012C121332964 @default.
• W4308182012 hasConceptScore W4308182012C126322002 @default.
• W4308182012 hasConceptScore W4308182012C141071460 @default.
• W4308182012 hasConceptScore W4308182012C17744445 @default.
• W4308182012 hasConceptScore W4308182012C1862650 @default.
• W4308182012 hasConceptScore W4308182012C189708586 @default.
• W4308182012 hasConceptScore W4308182012C198451711 @default.
• W4308182012 hasConceptScore W4308182012C199539241 @default.
• W4308182012 hasConceptScore W4308182012C27415008 @default.
• W4308182012 hasConceptScore W4308182012C2779134260 @default.
• W4308182012 hasConceptScore W4308182012C2779473830 @default.
• W4308182012 hasConceptScore W4308182012C61511704 @default.
• W4308182012 hasConceptScore W4308182012C71924100 @default.
• W4308182012 hasConceptScore W4308182012C95190672 @default.
• W4308182012 hasFunder F4320327235 @default.
• W4308182012 hasIssue "1" @default.
• W4308182012 hasLocation W43081820121 @default.
• W4308182012 hasLocation W43081820122 @default.
• W4308182012 hasLocation W43081820123 @default.
• W4308182012 hasLocation W43081820124 @default.
• W4308182012 hasOpenAccess W4308182012 @default.
• W4308182012 hasPrimaryLocation W43081820121 @default.
• W4308182012 hasRelatedWork W2098995101 @default.
• W4308182012 hasRelatedWork W2122489679 @default.
• W4308182012 hasRelatedWork W2550419422 @default.

• next